Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leanness Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

NCT01669174
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Interventions
Placebo, BYM338
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Torrance, California • Savannah, Georgia • Normal, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 1 Interventional

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

NCT00000646
View directory record Official record
Conditions
HIV Infections
Interventions
Pentoxifylline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

NCT00513357
View directory record Official record
Conditions
Gastrointestinal Cancer, Lung Cancer
Interventions
Melatonin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
Interventions
ponsegromab, Placebo for ponsegromab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Conway, Arkansas • Little Rock, Arkansas • North Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional

Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients

NCT03982082
View directory record Official record
Conditions
Cachexia, Malignant Solid Neoplasm
Interventions
Physical Therapy, Questionnaire Administration, Ultrasound
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 23, 2026, 8:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology

NCT03012139
View directory record Official record
Conditions
Metastatic Cancer, Cachexia; Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 23, 2026, 8:01 PM EDT
Not yet recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

NCT07663630
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Cachexia
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Decatur, Illinois • O'Fallon, Illinois • Garland, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

NCT00002067
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

NCT00004912
View directory record Official record
Conditions
Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
megestrol acetate, physical therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
North Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053
View directory record Official record
Conditions
Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Juven, Non-Juven Supplement
Dietary Supplement
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
17 Years to 120 Years
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
230
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

NCT01387269
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Fullerton, California • Glendale, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 23, 2026, 8:01 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437
View directory record Official record
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cash Plus Interventions for Prevention of Acute Malnutrition in Children Under 5 and Their Mothers in Somalia

NCT06642012
View directory record Official record
Conditions
Malnutrition, Child, Wasting Disease, Stunting, Malnutrition, Malnutrition, Mother
Interventions
Cash only, Cash + Social Behavior Change Communication, Cash + top-up cash
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
6 Months and older
Enrollment
3,384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

NCT05529849
View directory record Official record
Conditions
Cachexia
Interventions
TCMCB07, Placebo
Drug
Lead sponsor
Endevica Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

NCT02074995
View directory record Official record
Conditions
Hypercatabolic Status Related to Severe Burn
Interventions
BVS857, placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

NCT00219817
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291 HCl
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Greenbrae, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mitochondrial Respiratory Function in Mammalian Skeletal Muscle

NCT02650570
View directory record Official record
Conditions
Cancer, Cachexia
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Results available

Electronic-health Application To Measure Outcomes REmotely Clinical Trial

NCT02418546
View directory record Official record
Conditions
Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Cachexia
Interventions
In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

NCT00000737
View directory record Official record
Conditions
Cachexia, HIV Infections, HIV Wasting Syndrome
Interventions
Dronabinol, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Megace in HIV-Infected Women

NCT00002345
View directory record Official record
Conditions
Anorexia, Cachexia, HIV Infections
Interventions
Megestrol acetate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Sacramento, California • New Haven, Connecticut • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional

Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD

NCT02067377
View directory record Official record
Conditions
Advanced COPD (GOLD Stage 3 or 4) With Cachexia
Interventions
Serum bovine immunoglobulin (SBI) medical food, Placebo (for serum bovine immunoglobulin)
Dietary Supplement
Lead sponsor
Medical University of South Carolina
Other
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated No phase listed Observational

Uganda Birth Cohort Study

NCT04233944
View directory record Official record
Conditions
Birth Outcomes, Stunting, Wasting, Anemia
Interventions
Not listed
Lead sponsor
Tufts University
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
5,044 participants
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 8:01 PM EDT